Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
G-CSF Mobilized Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
Sponsor: Academy Military Medical Science, China
Listed as NCT02083718, this PHASE2 trial focuses on Hematological Diseases and Poor Graft Function and remains ongoing. Sponsored by Academy Military Medical Science, China, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Jul 2023 [monthly]
Unknown Status PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Dec 2019 [monthly]
Unknown Status PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academy Military Medical Science, China
- Guangdong Provincial People's Hospital
- Guangzhou General Hospital of Guangzhou Military Command
- Nanfang Hospital, Southern Medical University
- Peking University People's Hospital
- Shanghai Zhongshan Hospital
- Sun Yat-sen University
- Third Affiliated Hospital, Sun Yat-Sen University
For direct contact, visit the study record on ClinicalTrials.gov .